Intracoronary transplantation of autologous peripheral blood stem cells in old patients with acute myocardial infarction: 5-year postoperative evaluation of cardiac function

doi:10.3969/j.issn.2095-4344.2014.01.021

Abstract

Abstract:

BACKGROUND: Myocardial infarction patients commonly appear to have left ventricular remodeling and heart failure. Because of physical characteristics, these two complications are more likely to occur in elderly patients with myocardial infarction. In recent years, stem cell transplantation in the treatment of acute myocardial infarction and heart failure has become a hot topic, and the feasibility and safety has been confirmed, but its long-term outcomes in elderly patients are still unclear.
OBJECTIVE: To assess the long-term effect of transplantation of autologous peripheral blood stem cells on the left ventricular remodeling and heart function in the old patients with myocardial infarction.
METHODS: Thirty old patients (age ≥ 60 years) with myocardial infarction were randomly assigned to receive intracoronary transplantation of peripheral blood stem cells following bone marrow cells mobilization by granulocyte colony-stimulating factor ( 300-600 μg per day) subcutaneously for 5 days in addition to conventional therapy (standard drug therapy and percutaneous coronary intervention; transplantation group, n= 15) or standard therapy (standard drug therapy and percutaneous coronary intervention; control group, n=15) . Complications during intervention, left ventricular function and left ventricular remodeling at baseline and 6, 12, 24, 60 months after treatment were monitored.
RESULTS AND CONCLUSION: Left ventricular function, left ventricular end diastolic volume, and left ventricular end-systolic volume were significantly improved 6,12, 24, 60 months after autologous peripheral blood stem cell transplantation compared to baseline, while these parameters remained unchanged in the control group. These parameters had statistical difference between the two groups after treatment. During the follow-up, no severe side effects were observed. These findings indicate that autologous peripheral blood stem cell transplantation leads to significant and longstanding improvements in left ventricular performance of old patients with myocardial infarction, and shows good safety.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: myocardial infarction, aged, peripheral blood stem cell transplantation, transplantation, autologous

CLC Number:

R394.2

Yu Le, Zhang Ming. Intracoronary transplantation of autologous peripheral blood stem cells in old patients with acute myocardial infarction: 5-year postoperative evaluation of cardiac function[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(1): 125-130.

Figures/Tables 3

References

[1] Orlic D, Kajstura J, Chimenti S,et al.Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci. 2001;938:221-229.

[2] Boyle AJ, Schulman SP, Hare JM,et al. Is stem cell therapy ready for patients? Stem Cell Therapy for Cardiac Repair. Ready for the Next Step.Circulation. 2006;114(4):339-352.

[3] Hsieh PC, Segers VF, Davis ME,et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med. 2007;13(8): 970-974.

[4] Bergmann O, Bhardwaj RD, Bernard S,et al. Evidence for cardiomyocyte renewal in humans.Science. 2009;324(5923): 98-102.

[5] Kajstura J, Urbanek K, Perl S,et al. Cardiomyogenesis in the adult human heart. Circ Res. 2010;107(2):305-315.

[6] Fuchs S, Baffour R, Zhou YF,et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol. 2001;37(6):1726-1732.

[7] Bearzi C, Rota M, Hosoda T,et al. Human cardiac stem cells. Proc Natl Acad Sci U S A. 2007;104(35):14068-14073.

[8] Laugwitz KL, Moretti A, Lam J,et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005;433(7026):647-653.

[9] Wu SM, Fujiwara Y, Cibulsky SM,et al. Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart. Cell. 2006;127(6):1137-1150.

[10] Smith RR, Barile L, Cho HC,et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens.Circulation. 2007;115(7): 896-908.

[11] Segers VF, Lee RT.Stem-cell therapy for cardiac disease.Nature. 2008;451(7181):937-942.

[12] Schächinger V, Erbs S, Elsässer A,et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27(23):2775-2783.

[13] Mazhari R, Hare JM. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche.Nat Clin Pract Cardiovasc Med. 2007; 4 Suppl 1:S21-26.

[14] Hare JM, Traverse JH, Henry TD,et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.J Am Coll Cardiol. 2009; 54(24):2277-2286.

[15] Menasché P. Cell transplantation for the treatment of heart failure. Semin Thorac Cardiovasc Surg. 2002;14(2):157-166.

[16] Tomita S, Li RK, Weisel RD,et al. Autologous transplantation of bone marrow cells improves damaged heart function.Circulation. 1999;100(19 Suppl):II247-256.

[17] Okamoto K, Miyoshi S, Toyoda M,et al. 'Working' cardiomyocytes exhibiting plateau action potentials from human placenta-derived extraembryonic mesodermal cells. Exp Cell Res. 2007;313(12):2550-2562.

[18] Rafii S, Meeus S, Dias S,et al. Contribution of marrow-derived progenitors to vascular and cardiac regeneration.Semin Cell Dev Biol. 2002;13(1):61-67.

[19] Baffour R, Pakala R, Hellinga D,et al. Bone marrow-derived stem cell interactions with adult cardiomyocytes and skeletal myoblasts in vitro. Cardiovasc Revasc Med. 2006;7(4): 222-230.

[20] Robinson SN, Ng J, Niu T,et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006; 37(4):359-366.

[21] Meyer GP, Wollert KC, Lotz J,et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.Circulation. 2006;113(10): 1287-1294.

[22] Assmus B, Rolf A, Erbs S,et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail. 2010;3(1):89-96.

[23] Yousef M, Schannwell CM, Köstering M,et al. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol. 2009;53(24):2262-2269.

[24] Meyer GP, Wollert KC, Lotz J,et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J. 2009;30(24):2978-2984.

[25] Makkar RR, Smith RR, Cheng K,et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial.Lancet. 2012;379(9819):895-904.

[26] Huang RC,Yao K,Qian JY,et al.Emergency Intracoronary Stem Cell Transplantation in Patients with Acute Myocardial Infarction (TCT-STAMI-2): Long-Term Outcome .Circulation. 2008;118:S_791.

[27] Yousef M, Schannwell CM, Köstering M,et al. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction.J Am Coll Cardiol. 2009;53(24):2262-2269.

[28] Wang JS, Shum-Tim D, Galipeau J,et al. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg. 2000;120(5): 999-1005.

[29] Sedov VM, Nemkov AS, Afanas'ev BV,et al. Effectiveness of using autologous mono-nuclears of the bone marrow in treatment of patients with ischemic heart disease.Vestn Khir Im I I Grek. 2006;165(4):11-14.

[30] Mocini D, Colivicchi F, Santini M.Stem cell therapy for cardiac arrhythmias. Ital Heart J. 2005;6(3):267-271.

[31] Pannitteri G, Petrucci E, Testa U.Coordinate release of angiogenic growth factors after acute myocardial infarction: evidence of a two-wave production.J Cardiovasc Med (Hagerstown). 2006;7(12):872-879.

[32] Vasa M, Fichtlscherer S, Aicher A,et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89(1):E1-7.

[33] Seeger FH, Tonn T, Krzossok N,et al. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J. 2007;28(6):766-772.